|Elan ethics report scrutinized, Roche receives FDA Approval for Second-Generation Hepatitis B Viral Load Test|
|By Mary Davila|
|Wednesday, 22 September 2010 20:00|
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
Elan ethics report scrutinized over lawyer links - New questions have arisen about the independence of a report prepared by a U.S. law firm that cleared Irish drugmaker Elan Corp Plc (ELN.I) of any breaches of corporate governance or other wrongdoing. Elan, which faces mounting criticism from investors over its disclosure practices and perceived conflicts of interest in its business dealings, hired the firm of McKenna, Long & Aldridge earlier this year to investigate the allegations. The firm's recently completed report "found no legal breaches or other wrongdoing of any nature by Elan management, any members of its Board of Directors or its advisors," according to Elan, which has not released the contents of the report. But some experts and investors, including Ib Sonderby, an outspoken activist who has been campaigning for greater transparency at Elan, question the company's wisdom in hiring McKenna, Long & Aldridge.
Roche Receives FDA Approval for Second-Generation Hepatitis B Viral Load Test - Roche Molecular Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food & Drug Administration (FDA) has approved the COBAS® AmpliPrep / COBAS® TaqMan® HBV Test v2.0 for use in the United States. The new Roche test provides a fully automated solution for the quantitative detection of hepatitis B virus (HBV) DNA in human plasma or serum for patients on HBV antiviral therapy. "This new test enables clinicians to follow best practices in patient care with standardized viral load measurements, a broad range of detection, and high sensitivity," said Paul Brown, Ph.D., President and CEO of Roche Molecular Diagnostics. "The system is also carefully designed to protect the integrity of each patient result, so clinicians can make key medical decisions about therapy with confidence."
A5 Laboratories Inc. (OTCBB:AFLB) announced today that is has entered into an agreement with Mirador Consulting (www.miradorconsulting.com), a Florida based corporate consulting firm, to provide A5 Laboratories Inc. financial advisory and public relations representation in an effort to proactively and accurately present the Company to the public and investment community in a compliant, clear, and effective manner.
Alcon (NYSE: ACL), the world’s leading eye care company, announced the launch of its new combination anti-inflammatory/anti-infective product, TobraDex® ST suspension in the United States. TobraDex® ST (tobramycin/dexamethasone ophthalmic suspension) 0.3/0.05% is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or risk for infection exists.
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the company is scheduled to present at the Fifth Annual JMP Securities Healthcare Conference, Monday, September 27, 2010, at 2 p.m. Eastern Time in New York City.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the JMP Healthcare Conference being held in the New York Palace Hotel, New York City from September 27-28, 2010.
Chemspec International Limited (NYSE:CPC; "Chemspec" or the "Company"), a leading China-based contract manufacturer of highly-engineered specialty chemicals, today announced that its board of directors has authorized a share repurchase program that would allow the Company to repurchase up to US$10 million of its American Depositary Shares ("ADSs") on the open market between September 22, 2010 and September 21, 2011.
China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex:CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that the Company has successfully completed Phase I clinical trials of its novel cephalosporin-based combination antibiotic.
Eli Lilly and Company (NYSE:LLY) has been selected as one of the 100 Best Companies for Working Mothers by Working Mother magazine for the 16th consecutive year.
Endo Pharmaceuticals (Nasdaq:ENDP) announced that it recently received notification from the U.S. Food and Drug Administration (FDA) that Endo's new drug application (NDA) for its new oral formulation of long-acting oxymorphone, which is designed to be crush resistant, has been granted priority review status.
Inovio Pharmaceuticals, Inc. (NYSE Amex:INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO, will present a corporate overview at the investor conferences listed below.
Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNA-based drug discovery and development company, today announced that the first patient has received a novel cancer therapeutic candidate formulated in the Company's proprietary SMARTICLES® delivery technology.
Nano Mask, Inc. ("Nano Mask") (PINKSHEETS:NANM) today announced that it has launched a complete line of Nano Silver Technology Hospital Curtains which is being manufactured by an ISO 2010 certified manufacturer.
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it had reached an agreement with Seaside 88, LP ("Seaside"), a Florida limited partnership, for the exercise of Seaside's option to purchase an additional $2.5M of the Company's Series B Convertible Preferred Stock.
OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology.
Palatin Technologies, Inc. (NYSE Amex:PTN) will announce its fourth quarter, fiscal year 2010 financial results on Monday, September 27, 2010 before the open of the U.S. financial markets.
Protectus Medical Devices, Inc. (OTCQB: PTMD) (PINKSHEETS: PTMD), a developer and marketer of innovative safety medical devices, announces that the Company has been granted U.S. patent No. 7,799,002 ("Safety Syringe") by the U.S. Patent and Trademark Office.
pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back of the eye diseases, including the product candidate Iluvien for the treatment of Diabetic Macular Edema, today announced financial results for its fourth quarter and fiscal year ended June 30, 2010.
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics.
SGI (NASDAQ: SGI), a trusted leader in technical computing, today announced that the Agency for Science, Technology and Research (A*STAR) has purchased SGI Altix UV 1000, the world’s fastest, most scalable supercomputer, to accelerate public sector research and development in biomedical sciences, physical sciences and engineering.
Titan Pharmaceuticals, Inc. (OTC Bulletin Board:TTNP) today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction.
Valeant Pharmaceuticals International (NYSE:VRX) and Biovail Corporation (NYSE/TSX: BVF) today announced that Valeant currently anticipates declaring a one-time special cash dividend of $16.77 per share to Valeant stockholders on September 27, 2010 in connection with the previously announced merger transaction between Valeant and Biovail, subject to obtaining the requisite shareholder approvals in connection with the merger of Valeant and Biovail at their respective meetings of shareholders to be held on that date and to the satisfaction or waiver of certain conditions to the closing of the merger, including the receipt of financing.
ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market and begin distribution of the new Propaq® M Monitor, a vital signs monitor for deployable military medicine that was developed to meet the special needs of military customers and air medical operations worldwide.